异基因造血干细胞移植治疗儿童复发难治性非霍奇金淋巴瘤
该单中心回顾性研究纳入1998至2016年间接受异基因造血干细胞移植的36例儿童非霍奇金淋巴瘤患者,无论疾病风险均行异基因移植。3年总生存率为67%,间变性大细胞淋巴瘤为100%,淋巴母细胞淋巴瘤仅17%;
要点
- 异基因造血干细胞移植治疗儿童非霍奇金淋巴瘤3年总生存率67%,非复发死亡率仅6%。
- 间变性大细胞淋巴瘤3年总生存率100%,淋巴母细胞淋巴瘤仅17%。
- 移植前疾病状态显著影响预后:完全缓解100%,部分缓解59%,进展/稳定0%。
核心结论
- 异基因造血干细胞移植是儿童非霍奇金淋巴瘤耐受良好且有效的治疗选择,非复发死亡率和复发率低,但淋巴母细胞淋巴瘤移植时有活动性疾病者除外。
研究设计与样本
- 单中心回顾性研究,纳入1998至2016年间接受异基因造血干细胞移植的36例儿童非霍奇金淋巴瘤患者,无论疾病风险均行异基因移植。
主要发现
- 3年总生存率为67%。
- 3年总生存率因亚型而异:间变性大细胞淋巴瘤100%(n=14),弥漫大B细胞淋巴瘤63%(n=8),淋巴母细胞淋巴瘤17%(n=9),其他亚型合计80%(n=5)。
- 17例部分缓解患者中,6例淋巴母细胞淋巴瘤患者均死于疾病复发,其余11例移植后达缓解且无病生存。
临床怎么用
- 对于儿童复发难治性非霍奇金淋巴瘤,异基因造血干细胞移植可作为耐受良好且有效的治疗选择。
- 淋巴母细胞淋巴瘤患者若移植时存在活动性疾病,预后极差,需谨慎评估移植策略。
局限性
- 单中心回顾性研究,样本量较小(36例),部分亚型样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplant (HSCT) for relapsed pediatric non-Hodgkin lymphoma (NHL) is often reserved for patients with certain NHL subtypes or high-risk disease whereas the remainder receive autologous HSCT. Given the aggressive nature of pediatric NHL, we performed allogeneic HSCTs for all patients regardless of disease risk. We report overall survival (OS) and prognostic variables in 36 pediatric patients who underwent allogeneic HSCT between 1998 and 2016. OS at 3 years was 67%. The 3-year OS varied based on NHL subtype: 100% for anaplastic large cell lymphoma (n = 14), 63% for diffuse large B-cell lymphoma (n = 8), 17% for lymphoblastic lymphoma (LL; n = 9) and 80% for other subtypes combined (n = 5). Disease status influenced outcome with 3-year OS of 100% for patients in complete remission (n = 15), 59% with partial remission (PR; n = 17), and 0% with progressive/stable disease (n = 3) (P = .004). Of the 17 patients in PR, all 6 with LL died of relapsed disease, whereas the other 11 attained remission after HSCT and remained disease-free. The cumulative incidence of relapse after HSCT for LL was 78% compared with 15% for all other NHL subtypes combined (P < .0001). Cumulative incidence of nonrelapse mortality (NRM) was low in our cohort at 6%. Hence, allogeneic HSCT is a well-tolerated and useful therapeutic option with low rates of NRM and relapse for all NHL subtypes except LL with active disease at HSCT.
引用
- Naik S, Martinez CA, Omer B, et al. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019. PMID: 31511228. doi:10.1182/bloodadvances.2018026203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。